This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) Rises: Stock Adds 7.5% in Session
by Zacks Equity Research
Align Technology, Inc. (ALGN) rose over 7% in the last trading session.
Will Align Technology (ALGN) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Align Technology, Inc. (ALGN)
New Strong Buy Stocks for May 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Align Technology (ALGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings per share (EPS) of 85 cents in the first quarter of 2017, up 70% from 50 cents posted in the year-ago quarter.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release first-quarter 2017 results on May 9, after market close.
Medical Product Stocks' Earnings on Apr 27: ZBH, RMD & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their Jan-Mar 2017 quarter's reports on Apr 27.
Top Ranked Momentum Stocks to Buy for April 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 26th:
Align Technology (ALGN) Q1 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology, Inc. (ALGN) to beat expectations when it reports first-quarter fiscal 2017 results, after the market closes on Apr 27.
Anthem (ANTM) to Report Q1 Earnings: A Beat in the Cards?
by Zacks Equity Research
We expect Anthem Inc. (ANTM) to beat expectations when it reports first-quarter 2017 results on Apr 26, before the market opens.
Align (ALGN) Up 6.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Align (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align (ALGN) Upgraded to Buy on Invisalign System Prospects
by Zacks Equity Research
On Apr 11, leading provider of dental and oral care solutions, Align Technology Inc. (ALGN) was raised to a Zacks Rank #2 (Buy).
What's in Store for Walgreens Boots (WBA) in Q2 Earnings?
by Zacks Equity Research
Walgreens Boots Alliance, Inc (WBA) is slated to release second-quarter 2017 results, before the market opens on Apr 5.
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
Align's iTero Hits 1 Billion Mark, Boosts Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) has recently revealed that more than one million scans have been submitted using its iTero Element scanner in less than two years.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $110.87 on Mar 15, eventually closing a bit lower at $110.31.
Align Expands Internationally with Dental Couture Buyout
by Zacks Equity Research
Align Technology (ALGN) has recently announced the acquisition of Dubai, UAE and Nicosia, Cyprus-based distributor, G.L. Dental Couture Limited.
Align Technology (ALGN) Q4 Earnings and Revenues in Line
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.
Align Poised On Global Expansion & Invisalign Teen Growth
by Zacks Equity Research
On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Illumina (ILMN) Launches NovaSeq Series for $100 Genome
by Zacks Equity Research
Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
LLabCorp: Reimbursement Scenario a Drag Amid Other Woes
by Zacks Equity Research
On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.
ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders
by Zacks Equity Research
ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.
Myriad Genetics: Evidence Street Reviews EndoPredict Test
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.
Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.